ARCADIA BIOSCIENCES INC (RKDA)
NASDAQConsumer StaplesAgricultural InputsSnapshot 2026-09-04
$0.47+0.23%
Close 2026-09-04 · 1-day change
NASDAQConsumer StaplesAgricultural InputsSnapshot 2026-09-04
Broken: Primary pillar broken — Reduce net losses to improve financial health: EPS -2.09 vs target -1.3.
Arcadia Biosciences raised $4 million in June to support growth. Revenue rose from $901,000 in Q4 2025 to $1.1 million in Q1 2026. The company aims to improve financial results through cost management. These steps could help fix losses and improve value.
The company lost $4.4 million in Q1 2026, worse than before. Analysts expect revenue to drop about 33% next year. The stock price fell nearly 50% from its high. These show the turnaround is not working yet.
The market expects about 33% revenue decline next year. Our fair value is $1.93, close to the current price. We see the stock as cheap but risky given losses and weak outlook.
Breaks if: Capital raised is not used effectively to support growth
Implement strategies to increase shareholder value through capital allocation and strategic partnerships.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround situation with a focus on growth in the Consumer Staples sector. The current thesis is mixed, as management has set ambitious goals but has delivered inconsistent results.
The market seems to have priced in a low expectations gap, indicating that RKDA is seen as cheap compared to its peers. However, the fundamentals suggest that there is a significant risk of further declines if guidance is cut.
Fundamentals are likely to remain volatile due to the company's recent weak performance and high risk of missing earnings expectations. Management's focus on cost control has shown some success, but overall financial health remains a concern.
The thesis hinges on the company's ability to execute its growth plans for the Zola brand and manage costs effectively. Additionally, external factors like inflation trends and performance of sector leaders will play a crucial role in shaping future outcomes.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The company missed earnings expectations by $1.53. This indicates ongoing financial performance issues. The recent financial performance remains weak compared to its peers.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Net loss worsens beyond -$4.4 million next quarters
Focus on enhancing financial results through strategic initiatives and cost management.
Breaks if: Revenue falls below $1.1 million next quarter
Focus on enhancing financial results through strategic initiatives and cost management.
Over the next 1 to 3 years, RKDA's performance will depend heavily on management execution and market conditions in the Consumer Staples sector. Not investment advice.